Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer

INTRODUCTION: The multitargeted tyrosine kinase inhibitor (TKI) crizotinib is active against ALK translocated non-small-cell lung cancer (NSCLC); however acquired resistance invariably develops over time. ALK mutations have previously been implicated in only a third of resistant tumors. We sought to...

Full description

Saved in:
Bibliographic Details
Main Authors: Yamaguchi, Norihiro, Lucena-Araujo, Antonio R., Nakayama, Sohei, de Figueiredo-Pontes, Lorena L., Gonzalez, David A., Yasuda, Hiroyuki, Kobayashi, Susumu, Costa, Daniel B.
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3947244/
https://ncbi.nlm.nih.gov/pubmed/24199682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2013.09.019
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items